Amarin Shares Fall Despite Regulatory OK

Health and Healthcare

Published: July 27, 2012 11:23 am

Last Updated: July 27, 2012 11:24 am

Usually, shares of drug makers soar following the announcement that the Foood and Drug Administration approved a drug.

Amarin Corp. (NASDAQ: AMRN) announced approval by the FDA for Vascepta to patients very high triglycerides. Yet, shares of the company are down 9.89% to $13.80 on trading volume of 14 million shares. The 52-week high is $15.96.

A part of the problem is that the stock was rising, albeit slowly, throughout the week based on anticipation for the announcement. While the FDA approval was expected, it hasn’t yet received approval for New Chemical Entity status to make sure there isn’t a generic competitor.

Investors are also looking for the company to be sold. Companies that could be strong candidates include AstraZeneca PLC (LSE: AZN), Pfizer, Inc. (NYSE: PFE) and Abbott Laboratories (NYSE: ABT), according to a Bloomberg article on Friday.

Samuel Weigley

The Average American Is Losing Their Savings Every Day (Sponsor)

If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4% today, and inflation is much higher. Checking accounts are even worse.

Every day you don’t move to a high-yield savings account that beats inflation, you lose more and more value.

But there is good news. To win qualified customers, some accounts are paying 9-10x this national average. That’s an incredible way to keep your money safe, and get paid at the same time. Our top pick for high yield savings accounts includes other one time cash bonuses, and is FDIC insured.

Click here to see how much more you could be earning on your savings today. It takes just a few minutes and your money could be working for you.